Clinical Trial Update: Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome [Phase 4]

View source ↗

Summary

Phase 4 trial comparing secukinumab 300 mg with a lifestyle intervention versus secukinumab alone in adults with moderate-to-severe psoriasis and metabolic synd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis, Metabolic Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2026-04-22